Stockscreener 앱 받기
1.095
10.98%
-0.135
시간 외 거래:
1.14
0.045
+4.11%
전일 마감가:
$1.23
열려 있는:
$1.25
하루 거래량:
1.65M
Relative Volume:
3.65
시가총액:
$156.12M
수익:
-
순이익/손실:
$-35.47M
주가수익비율:
-1.9211
EPS:
-0.57
순현금흐름:
$-124.27M
1주 성능:
-27.00%
1개월 성능:
-29.35%
6개월 성능:
-54.37%
1년 성능:
-31.99%
1일 변동 폭
$1.09
$1.3152
1주일 범위
$1.09
$1.52
52주 변동 폭
$1.09
$4.44
Prokidney Corp Stock (PROK) Company Profile
명칭
Prokidney Corp
전화
336-999-7028
주소
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
PROK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.095 | 156.12M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-30 | 개시 | JP Morgan | Neutral |
| 2024-09-10 | 개시 | Guggenheim | Buy |
| 2024-03-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-01-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-07-25 | 개시 | BTIG Research | Buy |
| 2022-12-21 | 개시 | Jefferies | Buy |
| 2022-11-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-10-18 | 개시 | UBS | Buy |
| 2022-10-14 | 개시 | Citigroup | Buy |
| 2022-09-23 | 개시 | BofA Securities | Buy |
| 2022-09-02 | 개시 | Evercore ISI | Outperform |
모두보기
Prokidney Corp 주식(PROK)의 최신 뉴스
Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation - Simply Wall St
ProKidney (NASDAQ:PROK) Stock Price Down 2.7%Here's What Happened - MarketBeat
ProKidney stock hits 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa
ProKidney stock hits 52-week low at $1.34 amid market challenges - Investing.com
Head to Head Review: ProKidney (NASDAQ:PROK) and Adaptimmune Therapeutics (NASDAQ:ADAP) - Defense World
Owning 32% shares,institutional owners seem interested in ProKidney Corp. (NASDAQ:PROK), - Yahoo Finance
ProKidney Corp (NASDAQ: PROK) Has Great Upside Potential - Stocks Register
ProKidney Corp [PROK] Chief Regulatory Officer makes an insider sale of 16,412 shares worth 41,030. - Knox Daily
JPMorgan Chase & Co. Purchases 18,472 Shares of ProKidney Corp. (NASDAQ:PROK) - Defense World
Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm - The Malaysian Reserve
2025 Will Be A Major Year For ProKidney’s Rilparencel In CKD Treatment (NASDAQ:PROK) - Seeking Alpha
US Penny Stocks: 3 Picks With Market Caps Under $300M - Simply Wall St
ProKidney secures out-of-market buyer, $20.5 million price tag for Greensboro site - The Business Journals
ProKidney's high-profile Greensboro plant initiative ends with planned $20 million sale of property - Winston-Salem Journal
ProKidney (NASDAQ:PROK) Trading 8.7% HigherStill a Buy? - MarketBeat
Insiders In ProKidney Still Down 26% On US$54.7m Investment - Simply Wall St
Barclays PLC Has $281,000 Position in ProKidney Corp. (NASDAQ:PROK) - Defense World
568,647 Shares in ProKidney Corp. (NASDAQ:PROK) Purchased by Hennion & Walsh Asset Management Inc. - MarketBeat
Jane Street Group LLC Has $78,000 Stock Holdings in ProKidney Corp. (NASDAQ:PROK) - Defense World
ProKidney Corp (PROK) Analyst Thoughts: How High Can It Go? - Stocks Register
ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
ProKidney to Present at J.P. Morgan Healthcare Conference, Spotlight on CKD Cell Therapy - StockTitan
Geode Capital Management LLC Grows Stock Position in ProKidney Corp. (NASDAQ:PROK) - Defense World
Geode Capital Management LLC Raises Stake in ProKidney Corp. (NASDAQ:PROK) - MarketBeat
Barclays PLC Purchases 124,667 Shares of ProKidney Corp. (NASDAQ:PROK) - Defense World
One ProKidney Insider Raised Their Stake In The Previous Year - Yahoo Finance
Stories to Watch in 2025: Will ProKidney change its Winston-Salem plans after abandoning $458M Greensboro facility? - The Business Journals
Cortexyme (NASDAQ:CRTX) vs. ProKidney (NASDAQ:PROK) Head to Head Comparison - Defense World
State Street Corp Has $2.74 Million Holdings in ProKidney Corp. (NASDAQ:PROK) - Defense World
ProKidney (NASDAQ:PROK) Shares Gap UpStill a Buy? - MarketBeat
TBJ's Top 24 of '24: ProKidney backs out of Guilford deal, invests in W-S facilities (No. 4) - Triad Business Journal
ProKidney (NASDAQ:PROK) Stock Price Down 2.5%Here's What Happened - MarketBeat
ProKidney (NASDAQ:PROK) Stock Price Up 6.2%Should You Buy? - MarketBeat
ProKidney (NASDAQ:PROK) Shares Down 4.8%Here's What Happened - MarketBeat
ProKidney Corp. (NASDAQ:PROK) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Charles Schwab Investment Management Inc. Has $1.44 Million Holdings in ProKidney Corp. (NASDAQ:PROK) - MarketBeat
ProKidney (NASDAQ:PROK) Trading 5.9% HigherHere's What Happened - MarketBeat
Vigil Neuroscience (NASDAQ:VIGL) and ProKidney (NASDAQ:PROK) Head-To-Head Contrast - Defense World
JP Morgan Initiates Coverage of ProKidney (PROK) with Neutral Recommendation - MSN
ProKidney (NASDAQ:PROK) Trading 8.4% HigherWhat's Next? - MarketBeat
ProKidney (NASDAQ:PROK) Stock Price Up 5.4%Still a Buy? - MarketBeat
Suvretta Capital Management LLC Acquires 3,000,000 Shares of ProKidney Corp. (NASDAQ:PROK) - MarketBeat
ProKidney to Participate in Two Upcoming Conferences: - GlobeNewswire
Prokidney Corp (PROK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.45%
1.23%
자본화:
|
볼륨(24시간):